


**Remarks**

The Examiner has rejected the pending claims under 35 USC 102 (e) as being anticipated by Patent Application Publication No. US 2003/0032790 to Berkenstam et al. The Examiner states the Applicant's SEQ ID NO 14 is described in the cited reference in Figure 8 and that CYP3A4 activators are disclosed on page 4 paragraphs 61-78. The cited reference was filed August 31, 1998.

The 2003 Berkenstam publication lists priority references that were filed prior to the present application, namely, US Provisional Application No. 60/067,373 filed December 3, 1997, and Swedish applications SE 9703745-1, filed October 14, 1997, and SE 9801148-9, filed March 31, 1998. Applicants submit that the sequence of Figure 8 in the 2003 Berkenstam publication is not found in the 1997 references. Moreover, the CYP3A4 disclosure cited in the 2003 Berkenstam publication does not appear in any of the prior references. Thus, Applicants' invention was not described in a cited reference prior to invention, and is not anticipated under 35 USC 102(e). Copies of SE 9703745-1 and SE 9801148-9 and US Provisional Application No. 60/067,373 are included herewith.

Applicants respectfully request the rejection be withdrawn and request favorable reconsideration of the claims.

Respectfully Submitted,

  
Michael M. Conger  
Registration No. 43,562

Date: 7/2/07  
GlaxoSmithKline  
5 Moore Drive, P.O. Box 13398  
Research Triangle Park, NC 27709  
Tel: (919) 483-2474; Fax: (919) 483-7988